Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A1 | Q13285 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 3/20 | 0.47 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | RARB | P10826 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15740704 | 1.00 | NR5A1 (0.53) | NR5A1TP53TSHRLTA4HPLA2G4B | |
| SCHEMBL1109106 | 0.94 | CYP2D6 (0.47) | NR5A1LTA4HKDM4ENPC1MAPT | |
| SCHEMBL256095 | 0.87 | CHRNB2 (0.45) | LTA4HALDH1A1HPGDNPC1MAPT | |
| SCHEMBL25303652 | 0.82 | LSS (0.40) | NR5A1GAA | |
| SCHEMBL25261159 | 0.82 | LSS (0.40) | NR5A1GAA | |
| Dimethylamine SCHEMBL28977151 | 0.82 | PLK1 (0.44) | LTA4HALDH1A1HTTNPC1LMNA | |
| SCHEMBL18256805 | 0.80 | MAPT (0.59) | NR5A1TP53TSHRLTA4HPLA2G4B | |
| SCHEMBL7536641 | 0.80 | MAPT (0.59) | NR5A1TP53TSHRLTA4HPLA2G4B | |
| SCHEMBL7544659 | 0.80 | MAPT (0.59) | NR5A1TP53TSHRLTA4HPLA2G4B | |
| SCHEMBL7546685 | 0.80 | MAPT (0.59) | NR5A1TP53TSHRLTA4HPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3230276-B1 | GLP-1 RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2020-09-02 | — | — | EP | disclosed |
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2018-01-25 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| EP-3230276-A1 | GLP-1 RECEPTOR MODULATORS | Celgene International II Sarl (CH) | 2017-10-18 | — | — | EP | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
| WO-2016094729-A1 | GLP-1 RECEPTOR MODULATORS | CELGENE INTERNATIONAL II SARL (CH) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | NR5A1 857/4885TP53 4080/4885TSHR 45/4885 |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | NR5A1 857/4885TP53 4080/4885TSHR 45/4885 |
| US-10034886-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | NR5A1 692/4885TP53 3798/4885TSHR 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.